Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

Home

NVCR

N

NovoCure Limited (NVCR)

NMS – Real Time Price. Currency in USD

10.97

-0.79 (-6.72%)

At close: Mar 27, 2026, 4:00 PM EDT

11.02

+0.05 (0.46%)

After-hours: Mar 27, 2026, 7:52 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Videos

No Data

There is no data to display

Press releases

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq®), gemcitabine and nab-paclitaxel (gem/nab-pac) as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). PANOVA-4 met its pre-specified primary endpoint, achieving a statistically significant improvement in disease control rate (DCR) compared to the DCR reported.

Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Japan's Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua® through the country's National Health Insurance coverage. Optune Lua is approved in Japan for concurrent use with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on or after platinum-based chemotherapy. “Lung cancer remains one of the leading causes of cancer deaths in Japan. Healt.

Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update.

Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)

Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the province of British Columbia, Canada, will now cover Tumor Treating Fields (TTFields) therapy for the treatment of adult patients with newly diagnosed glioblastoma. British Columbia is the first province to provide coverage following Canada's Drug Agency's assessment and reimbursement recommendation for TTFields therapy in glioblastoma. “Glioblastoma is one of the most aggressive cancers, and treatment options.